191 related articles for article (PubMed ID: 26028371)
41. Survival in patients with parotid gland carcinoma - Results of a multi-center study.
Honda K; Tanaka S; Shinohara S; Asato R; Tamaki H; Maetani T; Tateya I; Kitamura M; Takebayashi S; Ichimaru K; Kitani Y; Kumabe Y; Kojima T; Ushiro K; Mizuta M; Yamada K; Omori K
Am J Otolaryngol; 2018; 39(1):65-70. PubMed ID: 29089142
[TBL] [Abstract][Full Text] [Related]
42. [Salivary duct carcinoma--a clinicopathological analysis of five cases].
Bień S; Sygut J; Kopczyński J; Postuła S; Ziółkowska M
Otolaryngol Pol; 2007; 61(1):33-8. PubMed ID: 17605416
[TBL] [Abstract][Full Text] [Related]
43. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status.
Nakano T; Yamamoto H; Hashimoto K; Tamiya S; Shiratsuchi H; Nakashima T; Nishiyama K; Higaki Y; Komune S; Oda Y
Histopathology; 2013 Sep; 63(3):378-92. PubMed ID: 23855785
[TBL] [Abstract][Full Text] [Related]
44. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour.
Etges A; Pinto DS; Kowalski LP; Soares FA; Araújo VC
J Clin Pathol; 2003 Dec; 56(12):914-8. PubMed ID: 14645349
[TBL] [Abstract][Full Text] [Related]
45. Acinic cell carcinoma of minor salivary glands: a clinical and immunohistochemical study.
Triantafillidou K; Iordanidis F; Psomaderis K; Kalimeras E
J Oral Maxillofac Surg; 2010 Oct; 68(10):2489-96. PubMed ID: 20678839
[TBL] [Abstract][Full Text] [Related]
46. Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.
Beck ACC; Lohuis PJFM; Al-Mamgani A; Smit LA; Klop WMC
Eur Arch Otorhinolaryngol; 2018 Jul; 275(7):1885-1892. PubMed ID: 29785551
[TBL] [Abstract][Full Text] [Related]
47. Salivary Duct Carcinoma with Invasive Micropapillary and Rhabdoid Feature Arising in the Submandibular Gland.
Otsuru M; Aoki T; Kondo Y; Ota Y; Sasaki M; Suzuki T; Ogura G; Kumaki N
Tokai J Exp Clin Med; 2017 Apr; 42(1):30-36. PubMed ID: 28413869
[TBL] [Abstract][Full Text] [Related]
48. [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands].
Golusiński W; Wegner A; Trzeciak P; Golusiński P; Sówka M; Kopczyński A; Bromboszcz M; Marszałek A
Otolaryngol Pol; 2013; 67(5):245-51. PubMed ID: 24021827
[TBL] [Abstract][Full Text] [Related]
49. Prognostic factors and survival rates for parotid duct carcinoma patients.
Shi S; Fang Q; Liu F; Zhong M; Sun C
J Craniomaxillofac Surg; 2014 Dec; 42(8):1929-31. PubMed ID: 25209384
[TBL] [Abstract][Full Text] [Related]
50. Cervical Lymph Node Metastatic Status and Adjuvant Therapy Predict the Prognosis of Salivary Duct Carcinoma.
Qian K; Di L; Guo K; Zheng X; Ji Q; Wang Z
J Oral Maxillofac Surg; 2018 Jul; 76(7):1578-1586. PubMed ID: 29544756
[TBL] [Abstract][Full Text] [Related]
51. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
Murata K; Kawahara A; Ono T; Takase Y; Abe H; Naito Y; Akiba J
Diagn Cytopathol; 2018 May; 46(5):429-433. PubMed ID: 29205961
[TBL] [Abstract][Full Text] [Related]
52. Carcinomas arising in the submandibular gland: high propensity for systemic failure.
Roh JL; Choi SH; Lee SW; Cho KJ; Nam SY; Kim SY
J Surg Oncol; 2008 May; 97(6):533-7. PubMed ID: 18286522
[TBL] [Abstract][Full Text] [Related]
53. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma.
van Boxtel W; Uijen MJM; Verhaegh GW; Willems SM; Jonker MA; ; Schalken JA; van Engen-van Grunsven ICH; van Herpen CML
Oral Oncol; 2020 Nov; 110():105018. PubMed ID: 33039794
[TBL] [Abstract][Full Text] [Related]
55. Distant Metastases in Patients with Carcinoma of the Major Salivary Glands.
Ali S; Bryant R; Palmer FL; DiLorenzo M; Shah JP; Patel SG; Ganly I
Ann Surg Oncol; 2015 Nov; 22(12):4014-9. PubMed ID: 25743328
[TBL] [Abstract][Full Text] [Related]
56. Prognostic factors in major salivary gland cancer.
Hocwald E; Korkmaz H; Yoo GH; Adsay V; Shibuya TY; Abrams J; Jacobs JR
Laryngoscope; 2001 Aug; 111(8):1434-9. PubMed ID: 11568581
[TBL] [Abstract][Full Text] [Related]
57. Salivary Duct Carcinoma of the Parotid: Outcomes with a Contemporary Multidisciplinary Treatment Approach.
Mifsud M; Sharma S; Leon M; Padhya T; Otto K; Caudell J
Otolaryngol Head Neck Surg; 2016 Jun; 154(6):1041-6. PubMed ID: 26980918
[TBL] [Abstract][Full Text] [Related]
58. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.
Ang KK; Berkey BA; Tu X; Zhang HZ; Katz R; Hammond EH; Fu KK; Milas L
Cancer Res; 2002 Dec; 62(24):7350-6. PubMed ID: 12499279
[TBL] [Abstract][Full Text] [Related]
59. Lymph node ratio predictive of recurrence, distant metastasis, and survival in submandibular gland carcinoma patients.
Cho WK; Roh JL; Cho KJ; Choi SH; Nam SY; Kim SY
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1055-1062. PubMed ID: 30806787
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
